CAT Sues Abbott Over Humira Royalties

Law360, New York (November 19, 2003, 12:00 AM EST) -- U.K. biotech company Cambridge Antibody Technology (CAT) filed a lawsuit in the High Court against Abbott Laboratories over hundreds of millions of dollars in royalty payments.

The lawsuit follows the breakdown of talks between the two companies over royalty payments for Humira, a treatment for rheumatoid arthritis.

CAT claims it is entitled to about 5.5% of Humira's sales under a licensing contract with Abbott. The U.S. drugmaker has made an initial 3% royalty payment and says it is allowed to offset the costs of its work...
To view the full article, register now.